Latest Deals
Credit: Shutterstock / JHVEPhoto
Baxter signs over kidney care arm to investment firm in $3.5bn deal
US medtech giant Baxter has signed a definitive agreement divesting itself of the kidney care segment, in a $3.5bn deal with global investment company Carlyle. The agreement comes following a March 2024 announcement in which the company detailed that it was looking to either spin out or sell off its kidney care wing. Now, the company says that its board determined that selling the business to Carlyle should maximise value for Baxter stockholders and best position Baxter and Vantive for long-term success.
Johnson & Johnson to acquire cardiovascular specialist V-Wave for up to $1.7bn
Johnson & Johnson (J&J) will acquire heart failure implant company V-Wave in a deal worth a potential $1.7bn, marking the latest billion-dollar boost to the medtech giant’s cardiovascular device portfolio. Expected to close by the end of this year, the deal will see V-Wave join J&J’s MedTech division. On top of the $600m upfront payment, the two companies have agreed to regulatory and commercial milestone payments of up to around $1.1bn.
Caresyntax raises $180m for AI surgery platform
Caresyntax has secured $180m as the company looks to expand the geographical reach of its AI-powered precision surgery platform. The round consisted of $80m in Series C extension equity and $100m of growth debt tied to milestones. Caresyntax says the company’s revenue increased by 75% in the first half of 2024, though it has not released financial figures.
HistoSonics raises $102m to advance non-invasive histotripsy platforms
HistoSonics has secured $102m in an oversubscribed Series D financing round to advance its non-invasive histotripsy platforms and support commercial growth. The round, which was led by Alpha Wave Ventures, is expected to help the company advance its histotripsy technology, aimed at treating liver tumours. The funding will also support the company’s commercial expansion in the US and planned international markets.
